Publications 2023-2024

1. *Biddle, Michael, et al."Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge", mAbs (2024), 16:1, https://doi.org/10.1080/19420862.2024.2323706
2.  Tsaknis, G; Virk H. "Assessment of solitary pulmonary nodule", BMJ Best Practice (2024).  (Online Resource)
3. Ayoubi, Riham, et al. "Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications." eLife 12:RP91645. (2023) https://doi.org/10.7554/eLife.91645.2 (lead UK author - designed analysis and contributed resources)
4. *Biddle, Michael and Virk, Harvinder S.” YCharOS Open Antibody Characterisation Data: Lessons Learned and Progress Made.” F1000Research 12 (2023). https://doi.org/10.12688/f1000research.141719.1
5. Kahn, Richard A., Harvinder S. Virk, and Peter S. McPherson. "Heed a decade of calls for antibody validation." Nature 620.7974 (2023): 492. https://doi.org/10.1038/d41586-023-02566-w
6. **Aponte Santiago, Nicole, et al. "Tales of the unexpected." eLife 12 (2023): e87444. https://doi.org/10.7554/eLife.87444

**Co-first author *Corresponding author

Preprints

1. Leavy, Olivia, et al. "Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosis." medRxiv (2024).01.12.24301204; doi: https://doi.org/10.1101/2024.01.12.24301204
2. Ayoubi, Riham, et al. A consensus platform for antibody characterization, 11 April 2024, PROTOCOL (Version 1) available at Protocol Exchange https://doi.org/10.21203/rs.3.pex-2607/v1 (lead UK author)

Current projects/ funding:-

NIHR INSPIRE Network INDEX (Interstitial Lung Disease Exacerbation) Study - National observational study to understand heterogeneity in care, management and outcomes of acute exacerbations of ILD

Biomarker discovery and target validation utilising the YCharOS antibody characterisation pipeline. Medical Research Council (Leicester) 2024-02 to 2024-11 | Locally awarded MRC Impact Accelerator with support from Leicester Drug Discovery and Diagnostics (PI)

The Only Good Antibodies Community Stakeholder Engagement Meeting. Biotechnology and Biological Sciences Research Council (Swindon). 2023-06 to 2024-03 | Locally awarded BBSRC Impact Accelerator, Event (PI)

Knowledge and skills exchange to lay the foundations for the international expansion of YCharOS: an Open Science, third party antibody characterisation public good company. Biotechnology and Biological Sciences Research Council IAA (Swindon). 2023-06 to 2024-03 | Locally awarded BBSRC Impact Accelerator, Exchange (PI)

Using fluorescent biosensors to understand mechanisms of lung ageing. Biotechnology and Biological Sciences Research Council (Swindon).(Co-PI) 2023-06 to 2024-03 | Locally awarded BBSRC Impact Accelerator, Proof of concept